Copyright: ©Author(s) 2026.
World J Diabetes. Oct 15, 2026; 17(10): 124271
Published online Oct 15, 2026. doi: 10.4239/wjd.124271
Published online Oct 15, 2026. doi: 10.4239/wjd.124271
Table 1 Comparison of baseline features of the training and validation cohorts, n (%)/mean ± SD
| Characteristic | Training cohort (n = 100) | Validation cohort (n = 43) | t/Z/χ2 | P value |
| Male | 62 (62.00) | 28 (65.10) | 0.125 | 0.723 |
| Age (year) | 70.28 ± 9.63 | 73.70 ± 10.42 | -1.898 | 0.060 |
| Diabetes duration (year) | 10.00 (5.00, 15.00) | 11.00 (8.00, 15.00) | -0.353 | 0.724 |
| Coronary heart disease | 27 (27.00) | 9 (20.90) | 0.588 | 0.443 |
| Cerebral infarction | 45 (45.00) | 14 (32.60) | 1.921 | 0.166 |
| Smoking | 43 (43.00) | 22 (51.20) | 0.808 | 0.369 |
| Drinking | 35 (35.00) | 18 (41.90) | 0.607 | 0.436 |
| Fontaine stage | -0.356 | 0.722 | ||
| II | 39 (39.00) | 13 (30.20) | ||
| III | 23 (23.00) | 15 (34.90) | ||
| IV | 38 (38.00) | 15 (34.90) | ||
| BMI (kg/m2) | 23.12 ± 3.98 | 22.11 ± 3.40 | 1.465 | 0.145 |
| Hb (g/L) | 122.81 ± 21.83 | 125.79 ± 18.36 | -0.784 | 0.435 |
| ALB (g/L) | 38.65 (36.43, 40.78) | 39.00 (34.30, 40.70) | -0.704 | 0.481 |
| ALT (U/L) | 14.00 (11.25, 22.00) | 14.00 (12.00, 19.00) | -0.659 | 0.510 |
| AST (U/L) | 16.00 (13.25, 21.75) | 16.00 (12.00, 19.00) | -0.814 | 0.416 |
| TBIL (μmol/L) | 9.45 (7.13, 13.43) | 8.92 (6.77, 12.28) | -1.054 | 0.292 |
| Scr (μmol/L) | 75.00 (60.25, 110.23) | 75.00 (57.00, 91.00) | -0.920 | 0.357 |
| FPG (μmol/L) | 7.05 (5.87, 8.84) | 6.58 (5.42, 8.31) | -1.072 | 0.284 |
| HbA1c (%) | 7.75 ± 1.59 | 7.36 ± 1.57 | 1.356 | 0.177 |
| TC (mmol/L) | 3.93 (3.09, 5.03) | 3.66 (3.07, 5.06) | -0.396 | 0.692 |
| TG (mmol/L) | 1.31 (0.98, 1.68) | 1.24 (0.97, 1.94) | -0.350 | 0.726 |
| LDL-C (mmol/L) | 2.57 ± 0.83 | 2.66 ± 0.85 | -0.538 | 0.591 |
| HDL-C (mmol/L) | 0.96 ± 0.25 | 1.03 ± 0.29 | -1.592 | 0.114 |
| FIB (g/L) | 4.04 (3.33, 5.24) | 3.78 (2.94, 4.62) | -1.149 | 0.251 |
| D-D (mg/L) | 0.49 (0.29, 0.84) | 0.43 (0.23, 0.70) | -1.231 | 0.218 |
| hs-CRP (mg/L) | 2.54 ± 1.25 | 2.29 ± 1.11 | 1.169 | 0.244 |
| TSP-4 (ng/mL) | 61.26 ± 29.46 | 64.47 ± 28.34 | -0.605 | 0.546 |
- Citation: Hu D, Lin XY, Zhao TQ, Ji H, Chen MW, Zhao XT. Clinical significance of serum thrombospondin-4 for interventional restenosis in diabetes patients complicated by lower extremity arteriosclerosis obliterans. World J Diabetes 2026; 17(10): 124271
- URL: https://www.wjgnet.com/1948-9358/full/v17/i10/124271.htm
- DOI: https://dx.doi.org/10.4239/wjd.124271